Company intelligence / Profile preview

Gifted Molecular Science

Incheon, Incheon-jikhal-si, Korea, Republic ofgiftedms.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Gifted Molecular Science is developing a proprietary PNA-based antiviral that directly targets the viral RNA genome. Their lead candidate GMS-007 is in preclinical development for COVID-19. The technology offers improved cell penetration and resistance to enzymatic degradation compared to conventional ASOs. Early data suggest potential applicability against a broad range of RNA viruses.

Therapeutic areas: Infectious Diseases
Modalities: Peptide nucleic acid (PNA)-based therapyAntisense oligonucleotide (ASO)
Industry: Biotech

Drug pipeline

1 asset

GMS-007

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on Gifted Molecular Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gifted Molecular Science.

Explore the full profile